<?xml version="1.0" encoding="UTF-8"?>
<p id="Par8">Table 
 <xref rid="Tab1" ref-type="table">1</xref> shows the clinical trials of repurposing various drugs as a possible therapeutic strategy against SARS-CoV-2 infection. Remdesivir, a nucleotide analog, is a broad-spectrum antiviral drug that inhibits RNA replication [
 <xref ref-type="bibr" rid="CR30">30</xref>] and may be a promising anti-viral drug therapy for COVID-19. Several studies demonstrated the effectiveness of remdesivir in animal models of SARS-CoV-2-related coronaviruses [
 <xref ref-type="bibr" rid="CR30">30</xref>, 
 <xref ref-type="bibr" rid="CR39">39</xref>â€“
 <xref ref-type="bibr" rid="CR41">41</xref>]. However, it was less effective against ebolavirus infections in humans [
 <xref ref-type="bibr" rid="CR42">42</xref>]. Recently, clinical trials of remdesivir against COVID-19 are ongoing primarily in the USA and China [
 <xref ref-type="bibr" rid="CR43">43</xref>].
</p>
